Treace Medical Concepts (TMCI) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $44.5 million, up 6% year-over-year, driven by increased case volumes, a growing surgeon base, and favorable product mix, particularly from SpeedPlate, Adductoplasty, and new technology adoption.

• Net loss widened to $21.2 million ($0.34 per share) from $12.3 million ($0.20 per share) in Q2 2023, reflecting higher operating expenses, strategic investments, and a one-time receivable write-off.

• Cash, cash equivalents, and marketable securities totaled $97 million as of June 30, 2024, with $54 million in outstanding debt.

• Strategic focus on expanding into the minimally invasive osteotomy market with new MIS platforms and a robust pipeline of over 10 products slated for commercialization through 2025.

• Reaffirmed full-year 2024 revenue guidance of $201–$211 million, representing 7–13% growth over 2023, and expects significant Adjusted EBITDA improvement.

Financial highlights

• Q2 2024 revenue was $44.5 million, a $2.5 million increase from Q2 2023; gross profit was $35.7 million.

• Gross margin for Q2 2024 was 80.2%, down from 81.7% in Q2 2023, due to product mix and higher costs.

• Operating expenses rose to $57.1 million from $47.3 million year-over-year, driven by sales, R&D, and corporate initiatives.

• Net loss attributable to common stockholders was $21.2 million ($0.34 per share), compared to $12.3 million ($0.20 per share) in Q2 2023.

• Cash and marketable securities totaled $95.1 million as of June 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $201–$211 million, up 7–13% year-over-year.

• Adjusted EBITDA for 2024 expected to improve by approximately 50% over 2023, with positive EBITDA targeted for 2025.

• Limited launch of new MIS osteotomy products in Q4 2024, with material impact expected in 2025.

• Ongoing investments in sales, marketing, and R&D are expected to drive long-term growth but will result in continued operating losses in the near term.

• Cash, marketable securities, and available debt are expected to fund operations for at least the next twelve months.